Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
PURPOSE: Preclinically, HIV protease inhibitors radiosensitize tumors with activated PI3-kinase/Akt pathway. We determined the toxicity of nelfinavir chemoradiotherapy in borderline resectable and unresectable pancreatic cancer. PATIENTS AND METHODS: Oral nelfinavir (2 x 1,250 mg) was started 3 days...
Main Authors: | Brunner, T, Geiger, M, Grabenbauer, G, Lang-Welzenbach, M, Mantoni, T, Cavallaro, A, Sauer, R, Hohenberger, W, Mckenna, W |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2008
|
Similar Items
-
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
by: Brunner, T, et al.
Published: (2008) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
by: Brunner, T, et al.
Published: (2008) -
Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation.
by: Tinkl, D, et al.
Published: (2009) -
ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir
in combination with chemoradiation for locally advanced inoperable
pancreatic cancer
by: Wilson, J, et al.
Published: (2016) -
The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells
by: Al-Assar, O, et al.
Published: (2016)